- HealthTech
- Tuesday, 09 Jun 2020
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
The new clinical manufacturing facility will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
This news follows WuXi Biologics' recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.
Related Industry Updates
North America Vaccines Market Outlook, Strategies, Manufacturers, Countries, Type and Application, Forecast To 2027I Merck, PFIZER, NOVAVAX
Jan 07, 2021
Patient-controlled Analgesic Infusion Pumps Market: Supply-Demand, Industry Research and End User Analysis, Outlook 2027
Feb 17, 2021
Europe Air Ambulance Services Market is expected to reach US$ 1318.5 Million by 2027 with CAGR of 7.0%
Sep 30, 2020
Bioburden Testing Market Worth Observing Growth | Thermo Fisher Scientific,Merck KGaA, bioMérieux SA
Apr 23, 2021
A U.S. Federal Regulator Initiated an Investigation into a Cloud Computing Deal Between Alphabet INC’s Google & Ascension Health
Nov 13, 2019
Point-of-Care Data Management Systems Market: Technological Growth Map with an Impact-Analysis
Dec 10, 2020
Asia Pacific Intraoperative Neuromonitoring Market Latest Report Analysis during 2019-2027| Medtronic, Natus Medical Incorporated, NuVasive, SpecialtyCare
Mar 11, 2021
Follow us on
